Meryl Bartlett is an associate in the Washington, D.C. office of Latham & Watkins.

Ms. Bartlett represents pharmaceutical, biotechnology, medical device, digital health, food, dietary supplement, cosmetic, and consumer product companies on FDA regulatory compliance and enforcement matters. She counsels at all stages of the product lifecycle, including, among others, pre-market regulatory communications and submissions, contract matters relating to clinical trials, non-patent exclusivity, post-market actions and recalls, and administrative interactions and appeals.

She also provides counsel on matters involving the Drug Enforcement Administration (DEA), US Department of Agriculture (USDA), and Federal Trade Commission (FTC). With the enactment of the Farm Bill in 2018, she also represents companies seeking to market CBD consumer products to navigate the evolving legal framework governing the industry.

In the transactional space, Ms. Bartlett advises investment banks, venture capital firms, private equity firms, and commercial lenders on regulatory diligence and disclosure matters in connection with mergers and acquisitions, equity offerings, financings, and other transactions in the life sciences sector.

Ms. Bartlett attended law school at the Georgetown University Law Center where she was a member of the Georgetown Law Journal and served as editor-in-chief of the Georgetown Law Journal’s Annual Review of Criminal Procedure.

Prior to joining Latham, Ms. Bartlett was an FDA regulatory associate at a national law firm in Washington, D.C. 

Bar Qualification

  • District of Columbia
  • Maryland

Education

  • JD, Georgetown University Law Center, 2017
  • BA in Law and Society & History, American University, 2014
    magna cum laude